GW4869 CAS NO.6823-69-4

1.we are direct manufacturerhave and we have 7 years experience in this aera.
2.we can provide competitive price for every customer and guarantee the quality of our goods.
3.Specials are possible when client's order is big enough, including the discount policy;
4.we promise we will return your money if our product don't have effect.
5.Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time;
6. Our customers may buy our products again after they use our sample.

GW4869 (10 μM) partially inhibits TNF-induced sphingomyelin (SM) hydrolysis, and 20 μM of the compound is protected completely from the loss of SM. The addition of 10-20 μM GW4869 completely inhibits the initial accumulation of ceramide, whereas this effect is partially lost at later time points (24 h). The action of GW4869 occurs downstream of the drop in glutathione. GW4869 is able, in a dose-dependent manner, to significantly protect from cell death. These protective effects are accompanied by significant inhibition of cytochrome c release from mitochondria and caspase 9 activation, therefore localizing N-SMase activation upstream of mitochondrial dysfunction^[1].

Pre-treatment with GW4869 significantly impairs release of both exosomes and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in RAW264.7 macrophages. At 12 h after LPS treatment or CLP surgery, WT mice pretreated with GW4869 displays lower amounts of exosomes and pro-inflammatory cytokines in the serum than control PBS-injected mice. Accordingly, GW4869 treatment diminishes the sepsis-induced cardiac inflammation, attenuates myocardial depression and prolongs survival^[2].

[1]. Luberto C, et al. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutralsphingomyelinase. J Biol Chem. 2002 Oct 25;277(43):41128-39.

[2]. Essandoh K, et al. Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. Biochim Biophys Acta. 2015 Nov;1852(11):2362-71.

Tianjin Kailiqi Biopharma Technology Co., Ltd, is a professional manufacturer specialized in the production and distribution of active pharmaceutical ingredients and intermediates. Our company has strong R&D ability and production experience to provide the customers new APIs. We specialize in developing innovative processes for the synthesis of a wide range of products. We also undertake custom synthesis and contract manufacturing.if you are interest in,pls contact with me,we also have Lab,specifical in some hard synthesis.